CAMBRIDGE, England, January 19, 2017 /PRNewswire/ --
Pfizer joins Astex, AstraZeneca, GlaxoSmithKline, Shionogi, MedImmune and Otsuka in the Milner Therapeutics Consortium
Major research investment to work with academic scientists in Cambridge
PFE) as a partner to the Milner Therapeutics Consortium. Pfizer has agreed to join the Consortium, which enables the efficient transfer of materials between industry and academia and allocation of funds for partnering opportunities in Cambridge. Dr Ron Newbold, Vice President, External R&D Innovation at Pfizer, will join the Milner Innovation Board alongside representatives from Astex, AstraZeneca, GlaxoSmithKline, Shionogi, MedImmune, University of Cambridge, Babraham Institute and Sanger Institute.
The Milner Therapeutics Consortium acts as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge and was established in 2015. The Consortium brings together the drug development capability of pharmaceutical companies with the know-how of entire academic institutions in Cambridge and has been specifically modelled to help facilitate the speedy exchange of resources and information between partners through a pre-signed agreement. Company partners are able to work individually with academics or through joint activities in order to help accelerate drug development. The Consortium’s Innovation Board includes companies and academic partners and is responsible for overseeing the strategic direction, collective research funding and collaborative activities.
Kathryn.chapman@milner.cam.ac.uk, +44-(0)1223-767111, http://www.milner.cam.ac.uk.
